The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.
The emergence of SARS-CoV-2 variants during the COVID-19 pandemic has demonstrated a need for broad immunization, such as provided by multivalent vaccines.
Stanford researchers have developed one of the smallest, active translational enhancers that can be adapted to control gene regulation. The translation enhancer is a short RNA stem-loop structure isolated from a Hox gene.
Stanford researchers have discovered that ribonucleoside vanadyl complexes can be used as an additive in transcription reactions resulting in ~2-fold increased yield.